PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be ...

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today and set a price target of $155.00.

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...